ROG: No rays of hope for TIGIT at ASCO2022
Roche recently announced the failure of co-primary progression free survival endpoints in both of its 1st line TIGIT trials in non-small (SK
top of page
Recent Research
Jun 21, 2022
NOVN Kisqali incumbent competitor Ibrance shows no OS benefit
ASCO2022 saw the eventual presentation of Pfizer's PALOMA-2 study, where, as we highlighted in our February 2020 Foveal report NOVN...
Jun 20, 2022
Bristol’s Breyanzi best in class; Opdivo+Yervoy longest survival ever lung & melanoma
ASCO 2022 saw publication of new data for Bristol's CD-19 CAR-T Breyanzi (liso cel) in large cell non-Hodgkin’s lymphoma, along with...
May 15, 2022
Bayer’s Factor XIa lower bleeding saw more strokes in small trial
We present an update on the state of the factor XI competitive market, building upon our previous analysis of three factor XI inhibitors for
Mar 7, 2022
JNJ: Novel next generation assets
We present an update to our September 2020 detailed pipeline analysis “J&J NME pipeline”, examining the prospects of three new molecular ent
May 10, 2017
Keytruda Chemo combo approved despite more deaths and no survival benefit
Last night the FDA granted accelerated approval for Merck’s Keytruda to be used in combination with pemetrexed and carboplatin chemo for...
May 9, 2017
ROG:XV: PDL1 Tecentriq predictably worse on overall survival than PD1s again
Predictable failure of ROG anti PDL1 Tecentriq in Bladder cancer where anti PD1 succeeded: As we feared, Roche today announced that its...
May 8, 2017
Anti PD-L1s continue lacklustre rivalry with anti PD-1s
AstraZeneca received accelerated FDA approval for its anti PD-L1 durvalumab (Imfinzi) in 2nd line bladder cancer last week, making this...
Apr 15, 2017
High Hurdle for IDOs
IDOs from Incyte are back in focus with high response rates and better safety than the existing IO combos. But will they win out...
Apr 3, 2017
ROG.VX: FDA Label-Ocrevus ineffective in women with breast cancer risk
Despite ROG last week’s Ocrevus FDA approval for PPMS & RRMS, its lack of benefit in women with PPMS and increased cancer risk and little di
Archive
Search By Tags
Follow Us
Bloomberg: FOVL <go>
ThomsonReuters
FactSet
Captial IQ
bottom of page